Why the study?
Does liraglutide improve endothelial dysfunction in patients with type 2 diabetes mellitus?
Cohort (n=52)
Open-label
No
Does liraglutide improve endothelial dysfunction in patients with type 2 diabetes mellitus?
Liraglutide improves vasomotor endothelial function in patients with type 2 diabetes mellitus, an effect that appears independent of its glucose-lowering capabilities.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for liraglutide's endothelial effects in T2DM; leaves open translation to cardiovascular outcomes.
Objective. To evaluate liraglutide (LIR) endothelial protective action. Material and methods. Type 2 diabetic patients with HbA1C 7.5-9.0 % had metformin (MET) dose titrated for 3 months. Patients with HbA1C less than 7.5 % comprised group 1 (MET), more than 7.5 % - group 2 (MET+LIR). Blood concentrations of tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), endothelin-1 (E) were evaluated at baseline, in 3, 6 and 9 months. Results. PAI-1 was increased in both groups and gradually decreased. T-PA was normal. E was primarily increased only in group 2. E was normal in group 1 in general, but enlarged with glycaemia increase. E decreased in group 2 with glycaemia improvement and worsening. Conclusions. Glycaemia control improvement decreases endothelial dysfunction. LIR improves vasomotor endothelial function, independently on its influence on glycaemia.
No takes yet. Share an insight, caveat, or question.
Симаненкова et al. (2018) conducted a cohort in Type 2 diabetes mellitus (n=52). Liraglutide vs. Metformin monotherapy was evaluated on Changes in endothelial dysfunction markers (endothelin-1, t-PA, PAI-1).
Synapse has enriched 10 related papers. Consider them for comparative context: